KODNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kodiak Sciences Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$91.35+5.60 (+6.53%)
Close on Oct 19, 2026
- Market cap
- $5.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 52.5% | -22.1% | -149.5% | |
| Return on assets | – | -18.7% | -66.9% | |
| Current ratio | – | 30.93 | 4.72 | |
| Interest coverage | -2858.5× | -5440.3× | – | |
| Diluted shares | 7M | 46M | 53M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kodiak Sciences generated $796.24M from operations and spent $96.28M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$796.24M
Used
$96.28M
Capital expenditure$96.28M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$229.97M
- Cash generatingOperating cash flow above zero-$136.01M
- Return on assets improvedROA up on the prior year-36.8% → -68.5%
- Earnings backed by cashOperating cash flow above net income-$136.01M vs -$229.97M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.72 → 4.72
- No dilutionShare count did not rise53M → 53M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –